Detection and significance of epidermal growth factor receptor mutation in esophageal, esophagogastric junction and gastric cancers

Chinese Journal of Oncology

Volumn 36, Issue 5, 2014, Pages 346-350

  Lyu, Xiao ^a   Huang, Jing ^b   Liu, Jian ^b   Wang, Wenna ^b   Su, Yiqun ^b   Zhang, Wen ^b   Sun, Yongkun ^b   Ying, Jianming ^b   Wang, Jinwan ^b   Sun, Yan ^b  

^a CANCER HOSPITAL   (China)

^b NONE

Author keywords

Esophageal neoplasms; Esophagogastric junction neoplasms; Gene expression; Mutation; Receptor, epidermal growth factor; Stomach neoplasms

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; EGFR PROTEIN, HUMAN;

ARTICLE; CANCER DIAGNOSIS; CHINESE; ESOPHAGUS CANCER; GENE MUTATION; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ESOPHAGUS TUMOR; EXON; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; SQUAMOUS CELL CARCINOMA; STOMACH TUMOR; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84921944762     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2014.05.006     Document Type: Article

References (20)

1. Huang J, Fail QX, Chen L, et al. Long-term outcomes of gemcitabine and cisplatin in patients with recurrent or metastatic esophageal squamous cell carcinoma: a phase II trial [J]. Chin Med J (Engl), 2011, 124(23):4012-4017.
2. Huang J, Zhou Y, Zhang H, et al. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy[J]. Med Oncol, 2013, 30(1):343.
3. Ilson DH, Kelsen D, Shah M, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus[J]. Cancer, 2011, 117(7):1409-1414.
4. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase I] trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOC 0127[J]. J Clin Oncol, 2006, 24(30):4922-4927.
5. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients [J]. J Clin Oncol, 2006, 24(10):1612-1619.
6. Adelstein DJ, Rodriguez CP, Rybicki LA, et al. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction[J]. Invest New Drugs, 2012, 30(4):1684-1689.
7. Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response[J]. Clin Cancer Res, 2007, 13(19):5869-5875.
8. Wang WP, Wang KN, Gao Q, et al. Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction[j]. World J Surg Oncol, 2012, 10:14.
9. Liu QW, Fu JH, Luo KJ, et al. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma[J]. Dis Esophagus, 2011, 24(5):374-380.
10. Ma HL, Xue YF, Li CS, et al. A preliminary study on K-ras EGFR, and B-raf mutations of esophageal squamous cell carcinoma [J]. Chin-Germ J Clin Oncol, 2011, 10(9):497-501.
11. Guo M, Liu S, Herman JG, el al. Cefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450[J]. Cancer Biol Ther, 2006, 5(2):152-155.
12. Abedi-Ardekani B, Dar NA, Mir MM, el al. Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia [J]. BMC Cancer, 2012, 12:602.
13. Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time[J]. Lancet Oncol, 2009, 10(5):432-433.
14. Pühringer-Oppermann FA, Stein HJ, Sarbia M. Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas[J]. Dis Esophagus, 2007, 20(1):9-ll.
15. Kwak EL, Jankowski J, Thayer SP, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas[J]. Clin Cancer Res, 2006, 12(14 Pt 1):4283-4287.
16. Becker JC, Müller-Tidow C, Slolte M, et al. Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer [J]. Int J Oncol, 2006, 29(3):615-623.
17. Liu Z, Liu L, Li M, el al. Epidermal growth factor receptor mutation in gastric cancer[J]. Pathology, 2011, 43(3):234-238.
18. Moutinho C, Mateus AR, Milanezi F, et al. Epidermal growth factor receptor structural alterations in gastric cancer [J]. BMC Cancer, 2008, 8:10.
19. Mammano E, Belluco C, Sciro M, et al. Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer[J]. Anticancer Res, 2006, 26(5A):3547-3550.
20. Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas [J]. J Clin Oncol, 2006, 24(11):1700-1704.